Department of Gastroenterological Surgery, Division of Gastroenterology, Hiroshima University Hospital, Kasumi 1-2-3, Minami-Ku, Hiroshima, 734-8551, Japan.
Department of Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Kasumi 1-2-3, Minami-Ku, Hiroshima, 734-8551, Japan.
Surg Today. 2024 Feb;54(2):177-185. doi: 10.1007/s00595-023-02715-8. Epub 2023 Jun 21.
The present study assessed the impact of pre- and postoperative tumor markers on the survival of patients with intrahepatic cholangiocarcinoma.
Medical records of 73 patients with intrahepatic cholangiocarcinoma were reviewed retrospectively. The pre- and postoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels were assessed. Patient characteristics, clinicopathological factors, and prognostic factors were analyzed.
The median recurrence-free survival and overall survival were 30.0 and 90.9 months, respectively. A multivariate survival analysis revealed that elevated postoperative carbohydrate antigen 19-9 (p = 0.023) was the only independent poor prognostic factor. The median overall survival of patients with normal and elevated postoperative carbohydrate antigen 19-9 levels was 101.4 and 15.7 months (p < 0.001), respectively. Multivariate logistic regression identified elevated preoperative carbohydrate antigen 19-9 as an independent preoperative risk factor for elevated postoperative carbohydrate antigen 19-9. The optimal cutoff value of preoperative carbohydrate antigen 19-9 for predicting elevated postoperative carbohydrate antigen 19-9 was 40 U/mL, with a sensitivity and specificity of 92% and 87%, respectively (area under curve = 0.915).
Elevated postoperative carbohydrate antigen 19-9 was an independent poor prognostic factor. Preoperative predictors, such as elevated preoperative carbohydrate antigen 19-9, may indicate the need for neoadjuvant therapies to improve the survival.
本研究评估了术前和术后肿瘤标志物对肝内胆管癌患者生存的影响。
回顾性分析了 73 例肝内胆管癌患者的病历。评估了术前和术后癌胚抗原和糖类抗原 19-9 的水平。分析了患者特征、临床病理因素和预后因素。
中位无复发生存期和总生存期分别为 30.0 和 90.9 个月。多变量生存分析显示,术后糖类抗原 19-9 升高(p=0.023)是唯一的独立不良预后因素。术后糖类抗原 19-9 正常和升高患者的中位总生存期分别为 101.4 和 15.7 个月(p<0.001)。多变量逻辑回归确定术前糖类抗原 19-9 升高是术后糖类抗原 19-9 升高的独立术前危险因素。术前糖类抗原 19-9 预测术后糖类抗原 19-9 升高的最佳截断值为 40 U/ml,其敏感性和特异性分别为 92%和 87%(曲线下面积=0.915)。
术后糖类抗原 19-9 升高是独立的不良预后因素。术前预测因子,如术前糖类抗原 19-9 升高,可能表明需要新辅助治疗以改善生存。